Baseball fans, get ready for a shake-up in the Pittsburgh Pirates' lineup! In a move that’s sure to spark debate, the Pirates have inked a $1.5 million, one-year deal with pitcher José Urquidy, adding a seasoned arm to their roster. But here's where it gets controversial—is this a smart investment for a team already boasting NL Cy Young Award winner Paul Skenes? Let’s dive into the details.
On Thursday, a source close to the negotiations confirmed to The Associated Press that Urquidy, a 30-year-old right-hander, has agreed to the deal, pending a successful physical. The agreement was kept under wraps until the health check clears, but it’s clear the Pirates are betting on Urquidy’s experience to bolster their pitching staff. What’s more, his contract allows him to be optioned to the minor leagues, giving the team valuable roster flexibility—a strategic move that could pay off big time.
Urquidy’s journey to Pittsburgh hasn’t been without hurdles. After undergoing Tommy John surgery on June 5, 2024, while with the Houston Astros, he signed a $1 million, one-year deal with the Detroit Tigers last March. He made his return to the majors on September 14, logging two relief appearances with a 7.71 ERA over 2 1/3 innings. While those numbers might raise eyebrows, here’s the part most people miss: Urquidy is a six-year major league veteran with a solid track record, boasting a 27-16 record and a 4.00 ERA in 70 starts and 11 relief appearances for the Astros (2019-23) and Tigers. His postseason stats are equally impressive, with a 4.08 ERA in 15 appearances, including eight starts.
But the question remains: Can Urquidy bounce back to his former glory after surgery and a rough 2023 season? And is this deal a calculated risk or a costly gamble for the Pirates? Some fans argue that his injury history makes this a risky move, while others believe his experience and postseason prowess are worth the investment. What do you think? Is Urquidy the missing piece the Pirates need, or is this deal destined for disappointment? Sound off in the comments—we want to hear your take!
